CORRIGENDUM

It has come to the authors' attention that their article entitled "Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial" (Global Health & Medicine. 2020; 2(4):240-246. DOI: 10.35772/ghm.2020.01050) included an error in Table 1. The corrected detailed is published with this corrigendum for your reading.

Table 1. Baseline characteristics of male and female patients.

Items	SOX/Bev (n = 250)				P	FOLFOX/Bev (n = 249)				P
	Male (n = 167)		Female (n = 83)			Male (n = 156)		Female (n = 93)
	n	%	n	%		n	%	n	%
Age
< 70	120	71.9	67	80.7	0.164	116	74.4	69	74.2	1.000
≥ 70	47	28.1	16	19.3		40	25.6	24	25.8
Primary lesion
Colon	80	47.9	48	57.8	0.422	76	48.7	47	50.5	0.225
Rectosigmoid	30	18.0	14	16.9		21	13.5	19	20.4
Rectum	55	32.9	20	24.1		59	37.8	27	29.0
Others	2	1.2	1	1.2		0		0
Differentiation assessed by histology
Well or moderate	148	88.6	67	80.7	0.223	135	86.5	77	82.8	0.331
Poorly	6	3.6	5	6.0		4	2.6	6	6.5
Other	13	7.8	11	13.3		17	10.9	10	10.8
Adjuvant chemotherapy for colorectal cancer
No	142	85.0	72	86.7	0.849	128	82.0	83	89.2	0.147
Yes	25	15.0	11	13.3		28	18.0	10	10.8
Target lesion
No	12	7.2	9	10.8	0.340	11	7.0	11	11.8	0.249
Yes	155	92.8	74	89.2		145	93.0	82	88.2
Liver metastases
No	45	26.9	38	45.8	0.004	53	34.0	34	36.6	0.683
Yes	122	73.1	45	54.2		103	66.0	59	63.4
Lung metastases
No	93	55.7	50	60.2	0.501	87	55.8	47	50.5	0.434
Yes	74	44.3	33	39.8		69	44.2	46	49.5
Lymph node metastases
No	123	73.7	66	79.5	0.350	119	76.3	67	72.0	0.456
Yes	44	26.3	17	20.5		37	23.7	26	28.0
Other metastases
No	135	80.8	53	63.9	0.005	136	87.2	70	75.3	0.024
Yes	32	19.2	30	36.1		20	12.8	23	24.7
Metastatic organs
1	73	43.7	38	45.8	0.788	83	53.2	44	47.3	0.432
≥ 2	94	56.3	45	54.2		73	46.8	49	52.7

P: Fisher's exact test. Bev, bevacizumab; FOLFOX, 5-FU/l-leucovorin plus oxaliplatin; SOX, S-1 plus oxaliplatin.